Title :

Outcomes after Allogeneic Hematopoietic Cell Transplant in patients diagnosed with Blast Phase of Myeloproliferative Neoplasms: a retrospective study from the Chronic Malignancies Working Party of the EBMT.

Author(s) :

Ortí, Guillermo [Auteur]
Vall d'Hebron Institute of Oncology [Barcelone] [VHIO]
Gras, Luuk [Auteur]
Universiteit Leiden = Leiden University
Zinger, Nienke [Auteur]
Leiden University Medical Center [LUMC]
Finazzi, Maria Chiara [Auteur]
Università degli Studi di Milano = University of Milan [UNIMI]
Sockel, Katja [Auteur]
University Hospital Carl Gustav Carus [Dresden, Germany]
Robin, Marie [Auteur]
Hopital Saint-Louis [AP-HP] [AP-HP]
Forcade, Edouard [Auteur]
Centre Hospitalier Universitaire de Bordeaux [CHU Bordeaux]
Avenoso, Daniele [Auteur]
King's College Hospital [KCH]
Kröger, Nicolaus [Auteur]
University Hospital Hamburg-Eppendorf
Finke, Jürgen [Auteur]

Radujkovic, Aleksandar [Auteur]
University of Heidelberg, Medical Faculty
Hunault-Berger, Mathilde [Auteur]
Centre Hospitalier Universitaire d'Angers [CHU Angers]
Schroyens, Wilfried [Auteur]
Antwerp University Hospital [Edegem] [UZA]
Zuckerman, Tsila [Auteur]
Bourhis, Jean-Henri [Auteur]
Institut Gustave Roussy [IGR]
Chalandon, Yves [Auteur]
Geneva University Hospitals and Geneva University
Bloor, Adrian [Auteur]
The Christie NHS Foundation Trust [Manchester, Royaume-Uni]
Schots, Rik [Auteur]
Universitair Ziekenhuis Brussel = University Hospital of Brussels [UZ Brussel]
De Wreede, Liesbeth C. [Auteur]
Leiden University Medical Center [LUMC]
Drozd-Sokolowska, Joana [Auteur]
Medical University of Warsaw - Poland
Raj, Kavita [Auteur]
University College London Hospitals NHS Foundation Trust [London, UK] [UCLH]
Polverelli, Nicola [Auteur]
Università degli Studi di Brescia = University of Brescia [UniBs]
Czerw, Tomasz [Auteur]
Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology [MCMCC]
Hernandez-Boluda, Juan Carlos [Auteur]
Universitat Politècnica de València = Universitad Politecnica de Valencia = Polytechnic University of Valencia [UPV]
Mclornan, Donal P. [Auteur]
University College London Hospitals NHS Foundation Trust [London, UK] [UCLH]
Yakoub-Agha, Ibrahim [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286

Journal title :

American Journal of Hematology

Abbreviated title :

Am J Hematol

Publication date :

2023-01-07

ISSN :

1096-8652

HAL domain(s) :

Sciences du Vivant [q-bio]

English abstract : [en]

Allogeneic hematopoietic cell transplant (allo-HCT) provides the only potential route to long-term remission in patients diagnosed with blast phase transformation of myeloproliferative neoplasm (BP-MPN). We report on a ...
Show more >Allogeneic hematopoietic cell transplant (allo-HCT) provides the only potential route to long-term remission in patients diagnosed with blast phase transformation of myeloproliferative neoplasm (BP-MPN). We report on a large, retrospective European Society for Blood and Marrow Transplantation registry-based study of BP-MPN patients undergoing allo-HCT. BP-MPN patients undergoing first allo-HCT between 2005 and 2019 were included. A total of 663 patients were included. With a median follow-up of 62 months, the estimated 3-year overall survival (OS) was 36% (95% confidence interval [CI], 32–36). Factors associated with lower OS were Karnofsky Performance Score (KPS) <90 (hazard ratio [HR] 1.65, p < .001) and active disease at allo-HCT (HR 1.45, p < .001), whereas patients undergoing allo-HCT more recently associated with a higher OS (HR 0.96, p = .008). In a selected patient's population, the 3-year OS of patients undergoing allo-HCT in complete response (CR) and with a KPS ≥90 was 60%. KPS < 90 (HR 1.4, p = .001) and active disease (HR 1.44, p = .0004) were associated with a lower progression-free survival (PFS). Conversely, most recent allo-HCT associated with a higher PFS (HR 0.96, p = .008). Active disease at allo-HCT (HR 1.34, p = .03) was associated with a higher cumulative incidence of relapse (RI) and allo-HCT in earlier calendar years (HR 0.96, p = .02) associated with a lower RI. Last, KPS < 90 (HR 1.91, p < .001), active disease (HR 1.74, p = .003) and allo-HCT from mismatched related donors were associated with a higher non-relapse mortality (HR 2.66, p = .003). In this large series of BP-MPN patients, about one third were alive at 3 years after transplantation. Patients undergoing allo-HCT in the more recent era, with a KPS ≥90 and in CR at transplant had a better prognosis.Show less >

Language :

Anglais

Audience :

Internationale

Popular science :

Non

Administrative institution(s) :

Université de Lille
Inserm
CHU Lille

Collections :

• Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286

Submission date :

2024-01-11T23:44:28Z
2024-03-27T10:41:21Z